Market Summary
USD20.59-0.65
Market Closed-3.06%
TNDM Stock Price
TNDM RSI Chart
TNDM Valuation
TNDM Price/Sales (Trailing)
TNDM Profitability
TNDM Fundamentals
TNDM Revenue
TNDM Earnings
Price Action
52 Week Range
20.5458.82
(Low)(High)
Last 7 days
-5.3%
Last 30 days
-27.1%
Last 90 days
-17.7%
Trailing 12 Months
-56.5%
TNDM Financial Health
TNDM Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TNDM
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Carpenter Rick | sold (taxes) | -3,066 | 21.75 | -141 | chief technical officer |
2023-09-15 | McGroddy-Goetz Kathleen | bought | 21,450 | 21.45 | 1,000 | - |
2023-09-15 | Carpenter Rick | acquired | - | - | 406 | chief technical officer |
2023-08-28 | Sheridan John F | sold (taxes) | -7,685 | 27.06 | -284 | president & ceo |
2023-08-28 | BERGER DAVID B | sold (taxes) | -3,815 | 27.06 | -141 | evp & chief operating officer |
2023-08-28 | Leal James | acquired | - | - | 310 | chief manufacturing officer |
2023-08-28 | HANSEN BRIAN B | acquired | - | - | 407 | evp & chief commercial officer |
2023-08-28 | HANSEN BRIAN B | sold (taxes) | -3,653 | 27.06 | -135 | evp & chief commercial officer |
2023-08-28 | BERGER DAVID B | acquired | - | - | 407 | evp & chief operating officer |
2023-08-28 | Gasser Elizabeth Anne | acquired | - | - | 372 | evp, chief strategy officer |
Which funds bought or sold TNDM recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 317,246 | 317,246 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -34.39 | -2,472,000 | 1,622,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 1.00 | -7,912 | 12,393 | -% |
2023-08-24 | Alberta Investment Management Corp | new | - | 4,644,170 | 4,644,170 | 0.04% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 81.13 | 40,702 | 471,168 | -% |
2023-08-21 | BOKF, NA | sold off | -100 | -491,015 | - | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 39.96 | -95,000 | 523,000 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.36 | -1,338,150 | 1,925,680 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 13.22 | -189,358 | 410,059 | -% |
2023-08-18 | Legato Capital Management LLC | added | 35.55 | -79,535 | 360,149 | 0.05% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Tandem Diabetes Care
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 12, 2023 | fmr llc | - | 0 | SC 13G/A | |
| May 10, 2023 | capital world investors | 10.0% | 6,473,192 | SC 13G/A | |
| Apr 10, 2023 | vanguard group inc | 10.92% | 7,047,477 | SC 13G/A | |
| Apr 06, 2023 | blackrock inc. | 14.3% | 9,206,880 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 7.7% | 4,978,524 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.53% | 6,127,229 | SC 13G/A | |
| Jan 24, 2023 | blackrock inc. | 9.9% | 6,345,760 | SC 13G | |
| Jul 11, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 5.6% | 3,543,503 | SC 13G/A |
Recent SEC filings of Tandem Diabetes Care
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 18, 2023 | 8-K | Current Report |
Peers (Alternatives to Tandem Diabetes Care)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.3B | 19.5B | 3.38% | 36.58% | 39.99 | 5.57 | 10.36% | 30.30% |
ISRG | 101.2B | 6.7B | -0.75% | 50.83% | 71.05 | 15.19 | 11.75% | -0.66% |
BSX | 77.5B | 13.4B | 6.45% | 36.39% | 85 | 5.78 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -4.29% | 12.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.3B | 5.7B | -8.22% | -17.24% | 30.48 | 7.49 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.65 | 10.11 | 16.30% | 250.21% |
SWAV | 7.1B | 616.6M | -12.54% | -24.86% | 29.24 | 11.56 | 69.52% | 343.68% |
GMED | 5.1B | 1.1B | -6.10% | -12.07% | 24.23 | 4.65 | 12.63% | 50.85% |
IRTC | 2.6B | 452.1M | -21.20% | -33.94% | -26.32 | 5.78 | 24.99% | 24.09% |
TNDM | 1.3B | 790.3M | -27.09% | -56.49% | -5.97 | 1.69 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -15.15% | 56.11% | -9.32 | 3.69 | 44.49% | -2.43% |
AVNS | 947.4M | 780.7M | -7.75% | -9.65% | -26.32 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 609.7M | 162.9M | -27.67% | -61.65% | -11.53 | 3.74 | 42.67% | 12.82% |
Tandem Diabetes Care News
Returns for TNDM
Cumulative Returns on TNDM
-18.2%
7-Year Cumulative Returns
-13.9%
5-Year Cumulative Returns
-42.5%
3-Year Cumulative Returns
Risks for TNDM
What is the probability of a big loss on TNDM?
100%
Probability that Tandem Diabetes Care stock will be more than 20% underwater in next one year
81.9%
Probability that Tandem Diabetes Care stock will be more than 30% underwater in next one year.
46.5%
Probability that Tandem Diabetes Care stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TNDM drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Tandem Diabetes Care was unfortunately bought at previous high price.
Drawdowns
Financials for Tandem Diabetes Care
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.5% | 790,349,000 | 794,694,000 | 801,218,000 | 790,712,000 | 765,792,000 | 737,669,000 | 702,799,000 | 660,868,000 | 604,844,000 | 541,941,000 | 498,830,000 | 439,163,000 | 410,217,000 | 394,236,000 | 362,305,000 | 330,106,000 | 281,713,000 | 222,584,000 | 183,866,000 | 147,961,000 | 128,700,000 |
| Gross Profit | -0.1% | 404,590,000 | 404,801,000 | 412,987,000 | 411,193,000 | 403,513,000 | 394,021,000 | 376,215,000 | 353,042,000 | 321,610,000 | 283,546,000 | 260,520,000 | 230,236,000 | 215,606,000 | 211,120,000 | 194,212,000 | 175,475,000 | 146,588,000 | 111,771,000 | 89,822,000 | 65,755,000 | 55,832,000 |
| Operating Expenses | 4.3% | 636,485,000 | 610,127,000 | 505,834,000 | 473,525,000 | 410,632,000 | 383,469,000 | 353,562,000 | 324,465,000 | 301,762,000 | 281,167,000 | 268,477,000 | 254,711,000 | 245,076,000 | 230,418,000 | 210,934,000 | 193,781,000 | 174,599,000 | 151,914,000 | 134,453,000 | 120,528,000 | 108,062,000 |
| S&GA Expenses | 4.8% | 369,220,000 | 352,224,000 | 335,681,000 | 309,488,000 | 290,307,000 | 276,216,000 | 261,508,000 | 244,527,000 | 229,832,000 | 213,749,000 | 204,903,000 | 195,947,000 | 190,368,000 | 180,493,000 | 165,735,000 | 152,353,000 | 137,210,000 | 119,273,000 | 105,226,000 | 94,348,000 | 84,967,000 |
| R&D Expenses | - | - | - | - | - | 120,325,000 | 107,253,000 | 92,054,000 | 79,938,000 | 71,930,000 | 67,418,000 | 63,574,000 | 58,765,000 | 54,709,000 | 49,926,000 | 45,199,000 | 41,428,000 | 37,389,000 | 32,641,000 | 29,227,000 | 26,181,000 | 23,096,000 |
| EBITDA | 100.0% | - | -183,668,000 | -76,239,000 | -44,901,000 | - | 20,810,000 | 31,914,000 | - | - | -13,112,000 | -24,375,000 | -42,328,000 | -37,293,000 | -10,320,000 | -18,904,000 | 6,823,000 | 11,542,000 | -106,310,000 | - | - | - |
| EBITDA Margin | 100.0% | - | -0.23 | -0.10 | -0.06 | - | 0.03 | 0.05 | - | - | -0.02 | -0.05 | -0.10 | -0.09 | -0.03 | -0.05 | 0.02 | 0.04 | -0.48 | - | - | - |
| Interest Expenses | - | - | - | 4,313,000 | 8,628,000 | - | - | 4,313,000 | 2,874,667 | - | - | 2,707,000 | - | - | - | - | 9,928,000 | 12,042,000 | - | 10,805,000 | 7,846,000 | 8,778,000 |
| Earnings Before Taxes | -10.8% | -221,681,000 | -200,052,000 | -92,852,000 | -65,599,000 | -12,499,000 | 4,601,000 | 15,901,000 | 21,738,000 | 6,569,000 | -26,731,000 | -36,282,000 | -50,640,000 | -44,100,000 | -16,412,000 | -24,604,000 | -8,682,000 | -6,048,000 | - | -122,560,000 | - | - |
| EBT Margin | 100.0% | - | -0.25 | -0.12 | -0.08 | -0.02 | 0.01 | 0.02 | 0.03 | 0.01 | -0.05 | -0.07 | -0.12 | -0.11 | -0.04 | -0.07 | - | - | - | - | - | - |
| Net Income | -10.2% | -224,470,000 | -203,751,000 | -94,593,000 | -67,933,000 | -13,169,000 | 5,895,000 | 15,566,000 | 21,758,000 | 6,556,000 | -24,559,000 | -34,382,000 | -48,730,000 | -42,223,000 | -16,628,000 | -24,753,000 | -23,719,000 | -55,063,000 | -112,910,000 | -122,611,000 | -137,703,000 | -119,492,000 |
| Net Income Margin | 100.0% | - | -0.26 | -0.12 | -0.09 | -0.02 | 0.01 | 0.02 | 0.03 | 0.01 | -0.05 | -0.07 | -0.11 | -0.10 | -0.04 | -0.07 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -21,944,000 | 16,367,000 | 30,063,000 | 50,879,000 | 83,175,000 | 97,179,000 | 94,431,000 | 71,186,000 | 49,819,000 | -2,739,000 | -1,186,000 | 9,406,000 | 500,000 | 22,365,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.8% | 947 | 954 | 1,053 | 1,048 | 1,037 | 1,015 | 905 | 850 | 795 | 754 | 716 | 673 | 616 | 343 | 326 | 293 | 255 | 215 | 206 | 182 | 158 |
| Current Assets | 0.8% | 764 | 758 | 850 | 834 | 835 | 818 | 812 | 755 | 698 | 662 | 637 | 592 | 540 | 281 | 276 | 247 | 213 | 186 | 188 | 163 | 128 |
| Cash Equivalents | 2.3% | 131 | 128 | 173 | 124 | 115 | 94.00 | 71.00 | 112 | 99.00 | 121 | 95.00 | 129 | 222 | 74.00 | 51.00 | 46.00 | 38.00 | 40.00 | 42.00 | 32.00 | 51.00 |
| Inventory | 12.2% | 148 | 132 | 111 | 105 | 88.00 | 80.00 | 69.00 | 66.00 | 67.00 | 67.00 | 64.00 | 71.00 | 62.00 | 60.00 | 49.00 | 41.00 | 27.00 | 23.00 | 20.00 | 24.00 | 25.00 |
| Net PPE | -1.1% | 74.00 | 75.00 | 69.00 | 73.00 | 59.00 | 50.00 | 50.00 | 50.00 | 49.00 | 50.00 | 50.00 | 49.00 | 44.00 | 38.00 | 33.00 | 28.00 | 23.00 | 17.00 | 17.00 | 18.00 | 18.00 |
| Liabilities | 0.3% | 617 | 615 | 613 | 626 | 587 | 578 | 472 | 461 | 449 | 441 | 350 | 346 | 349 | 136 | 131 | 126 | 110 | 94.00 | 75.00 | 66.00 | 132 |
| Current Liabilities | 2.0% | 175 | 171 | 165 | 174 | 139 | 132 | 132 | 120 | 109 | 103 | 104 | 106 | 114 | 100 | 99.00 | 100 | 84.00 | 77.00 | 66.00 | 59.00 | 43.00 |
| Shareholder's Equity | -2.8% | 329 | 339 | 440 | 422 | 450 | 437 | 433 | 390 | 346 | 313 | 366 | 327 | 268 | 207 | 195 | 167 | 145 | 121 | 131 | 115 | 26.00 |
| Retained Earnings | -4.2% | -888 | -853 | -729 | -713 | -664 | -649 | -634 | -645 | -651 | -655 | -659 | -676 | -666 | -639 | -624 | -627 | -624 | -623 | -600 | -603 | -569 |
| Additional Paid-In Capital | 2.3% | 1,219 | 1,192 | 1,171 | 1,140 | 1,118 | 1,090 | 1,068 | 1,035 | 997 | 968 | 1,025 | 1,003 | 934 | 847 | 820 | 794 | 770 | 744 | 731 | 719 | 595 |
| Accumulated Depreciation | - | - | - | 56.00 | - | - | - | 49.00 | - | - | - | 39.00 | - | - | - | 30.00 | - | - | - | 26.00 | - | - |
| Shares Outstanding | 0.7% | 65.00 | 65.00 | 65.00 | 64.00 | 64.00 | 64.00 | 64.00 | 63.00 | 63.00 | 62.00 | 62.00 | 62.00 | 60.00 | 60.00 | 59.00 | 59.00 | 58.00 | 58.00 | 48.00 | 56.00 | 51.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -72.1% | 5.00 | 18.00 | 50.00 | 64.00 | 74.00 | 96.00 | 111 | 107 | 87.00 | 74.00 | 25.00 | 29.00 | 37.00 | 25.00 | 42.00 | 37.00 | 10.00 | -0.17 | -8.32 | -34.09 | -49.65 |
| Share Based Compensation | 3.7% | 91.00 | 88.00 | 85.00 | 78.00 | 71.00 | 66.00 | 61.00 | 57.00 | 54.00 | 56.00 | 58.00 | 64.00 | 68.00 | 64.00 | 58.00 | 50.00 | 42.00 | 32.00 | 24.00 | 16.00 | 8.00 |
| Cashflow From Investing | -40.1% | 1.00 | 2.00 | 33.00 | -79.43 | -104 | -175 | -186 | -169 | -268 | -335 | -296 | -257 | -141 | -24.82 | -56.95 | -42.64 | -67.28 | -80.45 | -90.74 | -85.57 | -39.00 |
| Cashflow From Financing | -32.0% | 9.00 | 13.00 | 17.00 | 27.00 | 46.00 | 52.00 | 52.00 | 45.00 | 56.00 | 307 | 314 | 312 | 289 | 34.00 | 24.00 | 20.00 | 35.00 | 48.00 | 117 | 130 | 112 |
TNDM Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Sales | $ 195,917 | $ 200,262 | $ 365,300 | $ 376,169 |
| Cost of sales | 94,182 | 98,316 | 180,658 | 183,130 |
| Gross profit | 101,735 | 101,946 | 184,642 | 193,039 |
| Operating expenses: | ||||
| Selling, general and administrative | 97,610 | 80,614 | 187,424 | 153,885 |
| Research and development | 42,933 | 33,571 | 85,093 | 66,731 |
| Acquired in-process research and development expenses | 0 | 0 | 78,750 | 0 |
| Total operating expenses | 140,543 | 114,185 | 351,267 | 220,616 |
| Operating loss | (38,808) | (12,239) | (166,625) | (27,577) |
| Other income (expense), net: | ||||
| Interest income and other, net | 5,784 | 826 | 11,649 | 1,241 |
| Interest expense | (1,605) | (1,537) | (3,239) | (3,053) |
| Total other income (expense), net | 4,179 | (711) | 8,410 | (1,812) |
| Loss before income taxes | (34,629) | (12,950) | (158,215) | (29,389) |
| Income tax expense | 1,146 | 2,106 | 1,433 | 382 |
| Net loss | (35,775) | (15,056) | (159,648) | (29,771) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on short-term investments | (298) | (1,124) | 1,451 | (3,641) |
| Foreign currency translation losses | (802) | (97) | (827) | (25) |
| Comprehensive loss | $ (36,875) | $ (16,277) | $ (159,024) | $ (33,437) |
| Net loss per share - basic (in dollars per share) | $ (0.55) | $ (0.23) | $ (2.47) | $ (0.47) |
| Net loss per share - diluted (in dollars per share) | $ (0.55) | $ (0.24) | $ (2.47) | $ (0.47) |
| Weighted average shares used to compute basic net loss per share (in shares) | 64,830 | 64,077 | 64,690 | 63,979 |
| Weighted average shares used to compute diluted net loss per share (in shares) | 64,830 | 64,078 | 64,690 | 63,980 |
TNDM Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 130,751 | $ 172,517 |
| Short-term investments | 376,495 | 444,384 |
| Accounts receivable, net | 98,714 | 114,717 |
| Inventories | 147,599 | 111,117 |
| Prepaid and other current assets | 10,745 | 7,241 |
| Total current assets | 764,304 | 849,976 |
| Property and equipment, net | 73,752 | 68,552 |
| Operating lease right-of-use assets | 91,054 | 110,626 |
| Other long-term assets | 17,566 | 23,631 |
| Total assets | 946,676 | 1,052,785 |
| Current liabilities: | ||
| Accounts payable | 57,080 | 55,730 |
| Accrued expenses | 13,120 | 9,595 |
| Employee-related liabilities | 35,473 | 38,682 |
| Operating lease liabilities | 17,757 | 13,121 |
| Deferred revenue | 23,401 | 18,837 |
| Other current liabilities | 27,824 | 29,325 |
| Total current liabilities | 174,655 | 165,290 |
| Convertible senior notes, net - long-term | 284,128 | 283,232 |
| Operating lease liabilities - long-term | 118,400 | 123,524 |
| Deferred revenue - long-term | 15,305 | 16,874 |
| Other long-term liabilities | 24,954 | 23,918 |
| Total liabilities | 617,442 | 612,838 |
| Commitments and contingencies (Note 13) | 0 | 0 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000 shares authorized, 65,062 and 64,513 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively. | 65 | 65 |
| Additional paid-in capital | 1,219,199 | 1,170,888 |
| Accumulated other comprehensive loss | (1,193) | (1,817) |
| Accumulated deficit | (888,837) | (729,189) |
| Total stockholders’ equity | 329,234 | 439,947 |
| Total liabilities and stockholders’ equity | $ 946,676 | $ 1,052,785 |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.